Get started
Work

SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer

Year: 2025
Type: article
Study design: Observational Study
DOI: 10.1097/sla.0000000000006966
Authors: Julia Button, Elishama Kanu, Ethan Agritelley, Erin M. Dickey, Brian Diskin, Akshat Sarkari, Unaiza Zaman, Rajalaxmi Sharanappa, Annie Kim, Vanessa Marin-Guerra, David G. Brauer, Jashodeep Datta, Brock Hewitt, Michael E. Lidsky, Emil Lou, Nipun Merchant, Daniel Nussbaum, Susanna Ulahannan, Caitlin Hester, Brett L. Ecker
Institutions: Duke University, University of Miami, New York University, University of Minnesota, Masonic Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma, Rutgers Health, Rutgers Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4415616982
FWCI: 1.49
Cites:
Cited by: 4
Related to: